Oasamycin B is a member of the desertomycin family of 42-membered macrocyclic lactones with broad spectrum activity against Gram positive and Gram negative bacteria, yeasts and fungi. The oasamycins were first isolated by Zeeck and colleagues at the University of Gottingen, Germany in 1992. The oasamycins inhibit de novo cholesterol biosynthesis in the in vitro HEP‐G2 cell assay, being as potent as lovastatin. In a rat in vivo system, the A analogue of oasamycin B was as least as active as clofibrate in lowering serum cholesterol levels.